LakeShore Biopharma Co., Ltd (LSB) Financials
Newest figures come from the 10-K for FY2025, filed Jul 31, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LSB SEC filings page.
LakeShore Biopharma Co., Ltd (LSB) reported $85.7M in revenue for fiscal year 2025, up 6.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
LakeShore’s 2025 recovery came from sharply lower operating costs, while near-term liquidity remained tight against current obligations.
Revenue was broadly stable from FY2024 to FY2025, yet the operating margin recovered to-14.0% as R&D fell to$20.4M ; this points to spending normalization as the main recovery mechanism, not proven volume leverage.
Even after the operating loss narrowed, operating cash flow was
Current assets of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of LakeShore Biopharma Co., Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
LakeShore Biopharma Co., Ltd held $15.0M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $16.9M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and LakeShore Biopharma Co., Ltd scores 31/100 among other emerging companies.
LakeShore Biopharma Co., Ltd had 21M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and LakeShore Biopharma Co., Ltd scores 87/100 among other emerging companies.
LakeShore Biopharma Co., Ltd spent $20.4M on research and development in fiscal year 2025, which was 20.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and LakeShore Biopharma Co., Ltd scores 52/100 among other emerging companies.
LakeShore Biopharma Co., Ltd reported revenue of $85.7M in fiscal year 2025, against $80.8M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and LakeShore Biopharma Co., Ltd scores 34/100 among other emerging companies.
LakeShore Biopharma Co., Ltd's operations used $16.9M of cash in fiscal year 2025, against $41.6M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and LakeShore Biopharma Co., Ltd scores 65/100 among other emerging companies.
LakeShore Biopharma Co., Ltd's cash, cash equivalents and investments came to $15.0M at the end of fiscal year 2025, against $120.9M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and LakeShore Biopharma Co., Ltd scores 20/100 among other emerging companies.
LakeShore Biopharma Co., Ltd scores -2.08, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($25.8M) relative to total liabilities ($120.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
LakeShore Biopharma Co., Ltd passes 5 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
LakeShore Biopharma Co., Ltd reported a net loss of $13.9M while operations used $16.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
LakeShore Biopharma Co., Ltd reported an operating loss of $12.0M against $2.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
LakeShore Biopharma Co., Ltd held $15.0M in cash against $3.3M in long-term debt as of Q4 2025, with $114.9M of liabilities due within a year.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
LSB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q4'24 | Q4'23 |
|---|
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
LSB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q4'24 | Q4'23 |
|---|---|---|---|
| Total Assets | $190.5M-10.7% | $213.3M-14.8% | $250.3M |
| Current Assets | $117.3M-7.8% | $127.3M-15.6% | $150.8M |
| Cash & Equivalents | $15.0M-56.4% | $34.3M-36.3% | $53.9M |
| Inventory | $31.7M+10.6% | $28.7M+6.3% | $27.0M |
| Accounts Receivable | $69.8M+11.5% | $62.6M-7.1% | $67.4M |
| Total Liabilities | $120.9M-7.5% | $130.8M-9.3% | $144.3M |
| Current Liabilities | $114.9M+1.6% | $113.1M+17.9% | $95.9M |
| Non-Current Liabilities | $6.0M-66.0% | $17.7M-63.4% | $48.4M |
| Long-Term Debt | $3.3M-76.5% | $14.0M-67.4% | $42.8M |
| Total Equity | $69.6M-15.6% | $82.5M-22.2% | $106.0M |
| Retained Earnings | -$335.4M-3.1% | -$325.2M-19.3% | -$272.7M |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill.
LSB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q4'24 | Q4'23 |
|---|
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
LSB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q4'24 | Q4'23 |
|---|---|---|---|
| Current Ratio | 1.02-0.1x | 1.13-0.4x | 1.57 |
| Debt-to-Equity | 0.05-0.1x | 0.17-0.2x | 0.40 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| LakeShore Biopharma Co., Ltd LSB | FY2025 | $85.7M | -$13.9M | -16.3% | $25.8M | 48/100 |
| CASI Pharmaceuticals, Inc. CASI | FY2025 | $20.7M | -$48.1M | N/A | $4.3M | 21/100 |
| AN2 Therapeutics, Inc. ANTX | FY2025 | N/A | -$35.2M | N/A | $191.3M | — |
| Senti Biosciences Holdings, Inc. SNTI | FY2025 | $22K | -$61.4M | N/A | $10.1M | — |
| Dyadic International, Inc. DYAI | FY2025 | $3.1M | -$7.4M | N/A | $18.2M | 49/100 |
| Klotho Neurosciences, Inc. KLTO | FY2025 | N/A | -$10.6M | N/A | $56.7M | — |
Where LakeShore Biopharma Co., Ltd Ranks
Frequently Asked Questions
What is LakeShore Biopharma Co., Ltd's annual revenue?
LakeShore Biopharma Co., Ltd (LSB) reported $85.7M in total revenue for fiscal year 2025. This represents a 6.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is LakeShore Biopharma Co., Ltd's revenue growing?
LakeShore Biopharma Co., Ltd (LSB) revenue grew by 6.0% year-over-year, from $80.8M to $85.7M in fiscal year 2025.
Is LakeShore Biopharma Co., Ltd profitable?
No, LakeShore Biopharma Co., Ltd (LSB) reported a net income of -$13.9M in fiscal year 2025, with a net profit margin of -16.3%.
What is LakeShore Biopharma Co., Ltd's EBITDA?
LakeShore Biopharma Co., Ltd (LSB) had EBITDA of -$6.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does LakeShore Biopharma Co., Ltd have?
As of fiscal year 2025, LakeShore Biopharma Co., Ltd (LSB) had $15.0M in cash and equivalents against $3.3M in long-term debt.
What is LakeShore Biopharma Co., Ltd's gross margin?
LakeShore Biopharma Co., Ltd (LSB) had a gross margin of 82.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is LakeShore Biopharma Co., Ltd's operating margin?
LakeShore Biopharma Co., Ltd (LSB) had an operating margin of -14.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is LakeShore Biopharma Co., Ltd's net profit margin?
LakeShore Biopharma Co., Ltd (LSB) had a net profit margin of -16.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is LakeShore Biopharma Co., Ltd's return on equity (ROE)?
LakeShore Biopharma Co., Ltd (LSB) has a return on equity of -20.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is LakeShore Biopharma Co., Ltd's free cash flow?
LakeShore Biopharma Co., Ltd (LSB) recorded an outflow of $18.6M in free cash flow during fiscal year 2025. This represents a 61.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is LakeShore Biopharma Co., Ltd's operating cash flow?
LakeShore Biopharma Co., Ltd (LSB) recorded an outflow of $16.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are LakeShore Biopharma Co., Ltd's total assets?
LakeShore Biopharma Co., Ltd (LSB) had $190.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are LakeShore Biopharma Co., Ltd's capital expenditures?
LakeShore Biopharma Co., Ltd (LSB) invested $1.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does LakeShore Biopharma Co., Ltd spend on research and development?
LakeShore Biopharma Co., Ltd (LSB) invested $20.4M in research and development during fiscal year 2025.
What is LakeShore Biopharma Co., Ltd's current ratio?
LakeShore Biopharma Co., Ltd (LSB) had a current ratio of 1.02 as of fiscal year 2025, which is considered adequate.
What is LakeShore Biopharma Co., Ltd's debt-to-equity ratio?
LakeShore Biopharma Co., Ltd (LSB) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is LakeShore Biopharma Co., Ltd's return on assets (ROA)?
LakeShore Biopharma Co., Ltd (LSB) had a return on assets of -7.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does LakeShore Biopharma Co., Ltd's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, LakeShore Biopharma Co., Ltd (LSB) held $15.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $16.9M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is LakeShore Biopharma Co., Ltd's Altman Z-Score?
LakeShore Biopharma Co., Ltd (LSB) has an Altman Z-Score of -2.08, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is LakeShore Biopharma Co., Ltd's Piotroski F-Score?
LakeShore Biopharma Co., Ltd (LSB) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are LakeShore Biopharma Co., Ltd's earnings high quality?
LakeShore Biopharma Co., Ltd (LSB) reported a net loss of $13.9M while operations used $16.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can LakeShore Biopharma Co., Ltd cover its interest payments?
LakeShore Biopharma Co., Ltd (LSB) reported an operating loss of $12.0M against $2.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is LakeShore Biopharma Co., Ltd?
LakeShore Biopharma Co., Ltd (LSB) scores 48 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.